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Abstract 
We have investigated the effects that a tightly-bound water molecules has on the de novo 
design of cyclin-dependent kinase-2 (CDK2) ligands. In particular, we have analysed the 
impact of a specific water molecule on the chemical diversity and binding mode of ligands 
generated through a de novo structure-based ligand generation method in the binding site of 
CDK2.  The tightly-bound water molecule modifies the size and shape of the binding site and 
we have found that it also imposed constraints on the observed binding modes of the 
generated ligands. This in turn had the indirect effect of reducing the chemical diversity of the 
underlying molecular scaffolds that were able to bind to the enzyme satisfactorily. 
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1. Introduction 
The crystal structures of protein binding sites often reveal the presence of several water 
molecules. Some of these water molecules may be artefacts of the X-ray determination 1 
while others are loosely bound to the surface of the protein. However, a few water molecules 
are tightly bound to the surface, as revealed by their crystallographic order and the number of 
their interactions with the protein.2,3 Most drug design and ligand docking applications 
usually start by removing all water molecules from the binding site of a target protein. This is 
unlikely to be realistic, particularly when tightly-bound water molecules are present, as such 
solvent molecules provide hydrogen bonding groups that can mediate the interactions 
between the ligand and the protein. The resulting formation of a water-ligand-protein 
hydrogen-bonding network can help stabilise the ligand-protein interaction4-6 and may have a 
significant effect on the binding mode and even the chemical diversity of ligands binding to a 
given protein binding site. 
There is an increasing number of examples in the drug design literature where tightly-bound 
water molecules in the binding site of proteins have been mimicked or included.7-9 These 
applications reveal that displacing a tightly-bound water molecule by a ligand may improve 
the binding affinity, although this is not always the case.10  Other studies have shown that 
both natural substrates11 and designed inhibitors12 can make use of existing tightly-bound 
water molecules to “bridge” their interactions with the protein. Recent literature has also been 
providing examples of an increasing number of molecular modeling applications that make 
use of water molecules. It has been reported that ligand-protein docking13 and virtual 
screening of organic compounds14,15 can be improved by the presence of bound water 
molecules in the binding site of proteins.  Water molecules have also been used to distinguish 
the binding of different chemical scaffolds to a protein,15 to improve the predictive ability of 
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three-dimensional QSAR models16 and to aid in the structural interpretation of ligand-derived 
pharmacophore models of the binding sites of proteins.17 
A recent study on the use of tightly-bound water molecules in the de novo ligand design of 
molecular scaffolds for bacterial neuraminidase provided the first evidence of the influence 
that such water molecules can have in drug design.18  It was observed that the complete 
removal of all water molecules led to difficulties when generating any potential ligands. This 
was due to the fact that removing all tightly-bound water molecules left their now unsatisfied 
hydrogen-bonding groups beyond physical reach for a ligand to satisfy. As more of the water 
molecules that were identified as tightly bound were allowed in the binding site, the easier it 
became to generate ligands, which were also observed to be more chemically diverse. It was 
proposed that, in some cases, tightly-bound water molecules may in fact be more accessible 
for hydrogen bonding to an incoming ligand than the actual protein hydrogen-bonding groups 
associated with them. Water molecules may thus behave as versatile hydrogen-bonding 
groups and reduce the conformational constraints of a particular binding site. 
A recent validation study on the use of computer-aided de novo drug design showed that the 
Skelgen algorithm19,20 was able to generate representative molecular scaffolds of most 
inhibitor classes for a number of proteins of pharmaceutical interest.20 In this work we have 
analysed the crystal structures of these proteins and found that cyclin-dependant kinase 2 
(CDK2) contained a particularly relevant tightly-bound water molecule. We then proceeded to 
investigate in detail the effect of the presence of this water molecule during the in silico 
generation of representative molecular scaffolds.  We report our analysis of the variation in 
chemical diversity and binding mode of these molecular scaffolds. 
1.1 CDK2 binding site analysis 
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CDK2 is an enzyme implicated in cell division whose deregulated activity is thought to 
contribute to the initiation and progression of several diseases such as cancer, 
neurodegenerative and inflammatory disorders.21 Cyclin-dependent kinases catalyse the 
transfer of a phosphate group from ATP to a specific substrate aminoacid residue (serine or 
threonine), and the majority of drug discovery research in this area has been aimed at trying to 
produce small molecules that mimic ATP and bind competitively to its binding site.22-26 
Despite concerns about the selectivity of inhibitors among kinases based on designs using the 
ATP site, the discovery and ultimate development of potent and selective inhibitors, such as 
the anti-cancer drugs Gleevec and Iressa, have helped validate kinase inhibition as a 
therapeutic strategy,21,27 with many known ligands reported in the literature.28-30 
The binding mode of ATP has thus served as the basis for the search for new inhibitors of 
CDK2 because of its intermolecular interactions via its adenine ring to Glu 81 (Glu 75 in 
structure 1di8) and Leu 83 (Leu 77 in structure 1di8), as well as via its triphosphate group.  
Figure 1a shows the superposition (using residues Glu 81 and Leu 83 as reference) of the 
above-listed crystal structures, including their water molecules. All the ligands share a 
common flat orientation in the binding site. The two water molecules seen in Figure 1a 
interacting with Glu 81 and Leu 83 are found in the apo-enzyme (1hcl). Their presence 
confirms the importance of these hydrogen-bonding groups in the binding site.  An analysis of 
the ligands shown in Figure 1a reveal that these ligands are surrounded by water molecules 
that make various interactions with both the ligand and the protein. The phosphate group in 
particular exhibits this feature, as this highly charged group occupies regions of the binding 
site where extensive clusters and networks of water molecules can be seen. 
Figure 1b shows the (ATP) binding site of CDK2 with the inhibitor 4-[3-hydroxyanilino]-6,7-
dimethoxyquinazoline (as found in 1di8), with all hydrogen-bonding groups (which we refer 
to hereafter as sitepoints) that are available for ligand generation, as well as all identified 
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tightly-bound water molecules (see below).  Most known inhibitors of CDK2 interact with the 
backbone groups Glu 81 C=O, Leu 83 NH and Leu 83 C=O. Figure 1b shows these groups as 
hydrogen-bonding groups, as well as other groups in the enzyme binding site. The fused ring 
of the ligand interacts with the β-strand (residues 81-84, hinge region) which links the two 
domains of the protein.  It is interesting to note that this ligand seems to form two CH– –O 
hydrogen bonds with the protein.  This kind of non-standard hydrogen bond has been 
previously observed in heterocyclic kinase ligands.31  
2. Results and Discussion 
2.1 Identification of tightly-bound water molecules 
We have recently introduced a multivariate logistic method called WaterScore to discriminate 
between tightly-bound and displaceable water molecules in the binding sites of proteins.32   
Structural properties of water molecules in crystal structures such as the temperature B-factor, 
the solvent accessible contact surface area, the number of protein atom contacts and the 
hydrogen bond energy were analysed using a multivariate logistic regression approach. A 
probabilistic model was obtained, which can predict the likelihood of a water molecule being 











NPACbSCSAbBfbaA *321 +∗−∗−=  (2) 
where Bf is the B factor of a water molecule, SCSA is its solvent accessible contact surface 
area, and NPAC is the number of protein atomic contacts. P(Y=1) is the probability of a water 
molecule being classified as tightly bound, and the values of the different coefficients are a = 
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76.442, b1 = 5.278, b2 = 2.166 and b3 = 84.458. We can see that this model reflects the fact 
that tightly-bound water molecules will tend to have low B-factors, small solvent accessible 
contact surface areas and a large number of protein atomic contacts. Full details of this model 
can be found elsewhere.32 
By applying the above method to the crystal structure under study we found that three water 
molecules that are close to the ligand are predicted to be tightly-bound:  HOH 67, HOH 100 
and HOH 104 (numbering as assigned in crystal structure 1di8).  The position of these water 
molecules in the binding site of CDK2 can be seen in Figure 1b.  These water molecules are 
seen to participate in hydrogen bonding to important hydrogen-bonding groups in the binding 
site, as we discuss further below.  
2.2 De novo ligand design. 
Due to the pre-eminence of the interactions of known inhibitors of CDK2 with sitepoints Glu 
81 C=O, Leu 83 NH and Leu 83 C=O, a typical strategy for de novo ligand design involves 
generating molecular scaffolds that satisfy these three groups.20 There are several additional 
sitepoints in the vicinity of the above groups that are available for hydrogen-bonding and that 
may or may not be used by a bound ligand:  Asp 86 Oδ, Asp 86 N and Lys 89 Nζ. In the 
crystal structure of 1di8, the inhibitor does not interact directly with these sitepoints but a 
water molecule (HOH 100) interacts with most of them, as shown in Figure 1b. 
Figure 1b also reveals that the tightly-bound water molecules plays different roles in the 
binding of the inhibitor to CDK2. Water molecule HOH 67 interacts with Lys 89 Nζ, but it 
does not interact with the inhibitor in 1di8 and is in fact too far away to have a significant 
direct role in the binding of a ligand. Water molecule HOH 104 engages in hydrogen bonding 
with the inhibitor, but it does not obstruct the sitepoints that it interacts with (Lys 33 Nζ and 
Asp 145 Oδ) and is, consequently, unlikely to have a significant direct role in the binding of a 
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ligand. Water molecule HOH 100 interacts directly with the inhibitor and with sitepoints Asp 
86 Oδ and Asp 86 N, while being less than 4.5 Å away from Lys 20 Nζ. This water molecule 
partially blocks access to these sitepoints to an incoming ligand.  An analysis of the other 
CDK2 crystal structures reveals that HOH 100 is also found as HOH 38Z in 1h0w and HOH 
582 in 1dm2.  In most of the other crystal structures, this water position is occupied by a polar 
group in the ligands (such as a sulfonamide group). 
A recent molecular dynamics study of the hydration of the empty active site of CDK2 as well 
as complexed with ATP and two inhibitors has been recently reported.33 A number of 
identified tightly-bound water molecules are replaced by the purine ring of ATP and the 
inhibitors.  In particular, a water molecule (which corresponds to HOH 100 in 1di8) was seen 
to interact strongly with Asp 86 and was identified as a key tightly-bound water molecule 
mediating the interaction between the protein and the inhibitors,33 supporting our own finding 
that HOH 100 is a tightly-bound water molecule. 
On the basis of the above observations, we defined three strategies for de novo ligand 
generation. The first “standard” strategy (named A) was to generate ligands that satisfy only 
two or three of the three typical sitepoints (Leu 83 NH, Leu 83 C=O and Glu 81 C=O).  This 
is the same ligand design strategy adopted in an earlier validation study of Skelgen.20 The 
second strategy (named B) was to generate ligands that also satisfy these same sitepoints and 
water molecule HOH 100 (which can act as a hydrogen-bond donor or acceptor). The third 
strategy (named C) was to generate ligands that satisfy the above three typical sitepoints  and 
all the additional sitepoints that water molecule HOH 100 would otherwise block (Asp 86 Oδ, 
Asp 86 N and Lys 89 Nζ). This last strategy was adopted in order to generate ligands that 
would mimick the interactions of water molecule HOH 100 with the protein.  This approach 
has been demonstrated by the higher activities of –OH substituted purine-like inhibitors34 and 
the fact that several inhibitors interact with Asp 86.35,36  Table 1 summarises these three 
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strategies that we adopted for de novo ligand generation.  Each strategy allows the generation 
of ligands under different constraints as the shape and interaction properties of the binding 
site are modified in the presence or absence of the water molecule. 
It should be borne in mind that the above ligand generation strategies did not aim to fill the 
entirety of the binding site, but rather attempted to find molecular scaffolds that would satisfy 
the specific hydrogen bond interactions mentioned above. Satisfying these interactions alone 
does not lead to high affinity inhibitors, because binding affinity is also achieved through 
lipophilic interactions between the planar, mostly heterocyclic ring systems carrying the 
donor and acceptor groups that bind to the hinge region (Leu 83 and Glu 81) and surrounding 
aliphatic side chains.37 Furthermore, it is important to bear in mind that de novo ligand design 
methods may suggest chemically unreasonable or synthetically unfeasible molecules. 
Therefore we have focused our investigation to the analysis of known molecular scaffolds. 
2.3 Evaluation of de novo generated ligands 
Any minimised ligand that did not make hydrogen bonds with at least two out of the three 
typical sitepoints (Leu 83 NH, Leu 83 C=O and Glu 81 C=O) was discarded, as this has been 
observed to be an important requirement for biological activity.20  A further condition was 
that ligands were not allowed to use a hydroxyl group (-OH) to satisfy Leu 83 NH and Glu 81 
C=O simultaneously, since compounds of this type are known but have not led to any CDK2 
inhibitors of pre-clinical interest.20  When water molecule HOH 100 was present, ligands 
were further required to form a hydrogen bond to it. 
Once all ligands had been minimised and filtered, the molecular scaffolds involved in the 
interactions with the protein sitepoints (and the water molecule HOH 100, if present) were 
extracted, and any duplicates were removed.  The scaffolds were then manually classified 
according to their hydrogen-bonding patterns and binding modes. 
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2.4 Scaffold Analysis 
Table 2 lists all molecular scaffolds that were obtained with each ligand design strategy.  Each 
scaffold is identified by a number and subdivided into two classes (a and b) depending on 
their binding mode. Table 3 shows the chemical structures of these different scaffolds and 
illustrates schematically the possible two binding modes that were obtained with any (or all) 
of the three different ligand design strategies. Within this schematic representation, broken 
lines indicate hydrogen bonds, and water molecule HOH 100 and/or the additional sitepoints 
would be found at the bottom of each scaffold. 
We can see that the scaffolds fall naturally into different classes depending on their hydrogen-
bonding patterns with the three typical protein sitepoints (Glu 81 C=O, Leu 83 C=O and Leu 
83 NH), the nature of the donor and acceptor atoms on the scaffold, the number of bonds 
separating them, and the chemical type of ring they have. 
For example, scaffold 1a was found in the depicted binding mode within the ligands 
generated with all three ligand design strategies.  The same scaffold was also found with an 
alternative binding mode (shown in scaffold 1b).  Since the scaffold has rotated by about 180º 
it now has a different hydrogen bonding pattern with the three typical sitepoints.  Scaffold 1b 
was found with ligand design strategies A and C, but not with B (which included water 
molecule HOH 100). 
All of the nine molecular scaffolds that were found in a previous validation study of Skelgen20 
were identified with ligand design strategy A (using the typical sitepoints). These scaffolds 
are 1a (observed, for example, in the ligand in 1ckp), 2a (observed, for example, in the ligand 
in 1dm2), 3a (observed, for example, in the ligands in 1aq1, 1fvt, 1h0w  and 1ke5 to 1ke9), 4a 
(observed, for example, in the ligand in 1jvp), 5a, 6a, 7a, 8a (observed, for example, in the 
ligands in 1jsv and 1h0w) and 9a (observed, for example in the ligands in 1e1x, 1e1v, 1h0u, 
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1h0v and 1h0w).  It is worth noting that the earlier Skelgen validation study20 also correctly 
identified five chemical classes or binding motifs for CDK2 that had been previously 
determined. Several other scaffolds and their corresponding binding modes were also found 
with strategy A (as can be seen in Table 3). Interestingly, some of these scaffolds and binding 
modes were also found in the other two strategies (B and C). The ability to identify new 
chemical entities with new binding motifs has been proposed to be the highest value that de 
novo design can provide. 
ATP in one of the crystal structures of CDK2 (1hck38) has a binding mode like that one seen 
for scaffold 7a (except that ATP has a six-membered ring instead of the five-membered ring 
of scaffold 7a), with the two nitrogens of its six-membered ring participating in hydrogen-
bonding: N1 accepts a hydrogen bond from Leu 83 NH  and N6 donates a hydrogen bond to 
Glu 81 C=O. A series of inhibitors have been reported which have the structure of a modified 
guanine that interacts with the binding site in the same way as that for scaffolds 6a and 9a/b.37 
Scaffold 9a/b can also be seen in the ligands found in crystal structures 1e1v, 1e1x, 1h0u and 
1h0v.  This scaffold is symmetrical, and was generated with all three ligand design strategies, 
which indicates that it is a versatile scaffold that allows ligands that contain it to interact with 
all of the typical protein sitepoints and either water molecule HOH 100 or the additional 
sitepoints. The above examples illustrate the agreement that exists between the 
experimentally-observed binding modes of ATP and inhibitors of CDK2 and those of ligands 
generated in silico in this study. 
The molecular structure of scaffold 7b is contained in recently disclosed clinical candidates 
for drugs that inhibit CDK2,39 and is shown in Figure 2. The crystal structure has not yet been 
disclosed for the structure of CDK2 complexed with this inhibitor. Our modeled binding 
mode of this molecule in the binding site of CDK2 found that the core interactions with Glu 
81 and Leu 83 are preserved and that the piperazine ring of the ligand occupies the position of 
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water molecule HOH 100, indicating that this inhibitor displaces this water molecule upon 
binding. The reported pictorial representation of the crystal structure of this inhibitor bound to 
CDK2 appears to confirm this prediction.39 
Ligands that combine several of the molecular scaffolds and binding modes shown in Table 2 
are of interest because they are likely to have appropriate interactions with the protein that 
would enhance ligand binding. Such ligands might be useful in the search for new lead 
compounds. For example, the ligand shown in Figures 3a and 4a (generated with design 
strategy B) combines the hydrogen-bonding interactions of scaffolds 6b and 7a, as well as 
hydrogen bonding with water molecule HOH 100. 
An important observation is needed here before proceeding to analyse the effect of the 
presence of the tightly-bound water molecule. The use of more sitepoints (ligand design 
strategies B and C) would inevitably lead to the generation of larger ligands due to the larger 
distance between all sitepoints considered. Therefore, it was necessary to compare the 
structures and binding modes only in the region of the typical protein sitepoints (Glu 81 C=O, 
Leu 83 C=O and Leu 83 NH) in order to distinguish the effects produced by the presence of 
water molecule HOH 100 or the additional sitepoints. This would allow us to investigate the 
availability of specific molecular scaffolds and their binding modes near the common typical 
protein sitepoints under the influence of the tightly-bound water molecule and/or its 
associated additional sitepoints. 
All of the scaffolds generated with ligand design strategy B (with water molecule HOH 100) 
were also generated with design strategies A and C (except for scaffold 17a, which was not 
generated with design strategy C). On the other hand, several scaffolds and/or their alternative 
binding modes were only generated with design strategies A and C, but not with design 
strategy B. This suggests that it is more difficult (i.e. the chemical diversity is more limited) 
to find a ligand that can interact with the typical protein sitepoints and with the water 
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molecule. Figure 3b shows the sideview of the binding mode of the ligand shown in Figure 3a 
(its chemical structure is shown in Figure 4a). This ligand can interact with all three typical 
sitepoints and with water molecule HOH 100. We can see that these sitepoints and the water 
molecule lie in a common plane within the binding site. It is possible that such arrangement 
introduces what we have named as geometric constraints on the placement of molecular 
scaffolds, where only certain scaffolds can be used in ligands that can satisfy all hydrogen 
bonding interactions and have substituent groups at an appropriate hydrogen-bonding distance 
from the water molecule (close enough to form a hydrogen bond but not too close to give rise 
to a steric clash).  
Nearly all of the scaffolds generated with ligand design strategy B interact with the protein by 
forming hydrogen bonds with both the Leu 83 NH and Leu 83 C=O sitepoints. Few cases 
were found in which a scaffold was interacting with both the Leu 83 NH and Glu 81 C=O 
sitepoints (scaffolds 8b and 10a), and there was only one scaffold that interacted with all three 
sitepoints (the symmetric scaffold 9a/b). However, there were multiple instances of ligands 
that were generated with design strategies A and C that had scaffolds which made hydrogen 
bonds to both Leu 83 NH and Glu 81 C=O. It then becomes apparent that including the 
tightly-bound water molecule HOH 100 as an interaction sitepoint restricts the binding modes 
available to molecular scaffolds and, in doing so, restricts the chemical diversity of the 
scaffolds that can be generated. Consequently, in the presence of water molecule HOH 100 it 
is easier to generate ligands that form hydrogen bonds with both Leu 83 NH and Leu 83 C=O 
and which are also able to form hydrogen bonds with the water molecule. An example of this 
type of molecular scaffold in a ligand structure can be seen in Figure 3c, while its 
corresponding chemical structure is shown in Figure 4c. The hydrogen-bonding interactions 
of this ligand with the typical protein sitepoints are provided by a combination of the 
interactions seen in the binding modes of scaffolds 11b and 15b (as shown in Table 2).  
Figure 3d, on the other hand, shows a ligand containing scaffold 16b that was generated with 
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strategy C but that was not found with strategy B.  This scaffold (in conjunction with scaffold 
3a) can be found in the ligands of crystal structures 1ke5 to 1ke9. We can see that the scaffold 
itself has a steric clash with water molecule HOH 100, preventing it from being incorporated 
into any ligand in a design strategy that incorporates this water molecule. The chemical 
structure of the ligand is shown in Figure 4d. All of the above observations portray a picture 
where a structure-based drug design strategy that includes tightly-bound water molecules may 
have a significant effect on the types of molecular scaffolds and ligands (and their binding 
modes) that can be generated. 
It is difficult to assess whether ligands that possess appropriate molecular scaffolds that would 
allow them to interact with water molecule HOH 100 have better binding affinities to CDK2.  
In addition to the anilinoquinazoline ligand found in 1di8, there are other inhibitors that 
appear to interact with this water molecule when bound to the active site of CDK2, such as 
roscovitine33,40 and isopentenyladenine.33,41 Nonetheless, it has been suggested that the 
appropriate replacement of tightly-bound water molecules in the active site of CDK2 may 
result in an increase in binding affinity.33 As more crystal structures become available it may 
be possible to determine unambiguously the binding mode of some of the molecular scaffolds 
that we have investigated in this study. Furthermore, an experimental determination of the 
binding constants of ligands containing such scaffolds would help establish the relative 
importance of water molecule HOH 100 as it bridges the interaction between the ligands and 
the protein.  
3. Conclusions 
We have studied the effects that an experimentally-observed tightly-bound water molecule 
has on the computer-aided de novo design of CDK2 ligands. Ligand generation was carried 
out to satisfy a set of typical and widely-used protein hydrogen-bonding groups and either a 
neighbouring tightly-bound water molecule or its associated hydrogen-bonding groups (which 
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are not accessible when the water molecule is present). This in silico approach has yielded a 
significant number of known binding motifs, some of which can be observed in known active 
compounds. A number of new binding motifs have also been generated, corroborating the 
utility of de novo ligand design for suggesting novel chemical entities. 
We have observed that the tightly-bound water molecule modifies the size and shape of the 
binding site and, more importantly, we have also found that it imposes constraints on the 
observed binding modes of the generated ligands. This is due to the specified requirement that 
generated ligands have to interact (through hydrogen bonding) with this water molecule. 
Ligands generated under these conditions exhibit more restricted hydrogen-bonding patterns 
within the binding site, which in turn is translated into a reduced chemical diversity of the 
underlying molecular scaffolds. 
Complementary to the finding that, in some cases, tightly-bound water molecules satisfy 
hydrogen-bonding groups that would be otherwise inaccessible to an incoming ligand,18 we 
have concluded that tightly-bound water molecules may have an influential role in 
determining the binding modes and chemical diversity of molecular scaffolds.  These findings 
have implications for drug design strategies that make use of tightly-bound water molecules 
as potential hydrogen-bonding groups. 
4. Experimental 
A survey of the Protein Data Bank42 was used to obtain a selection of 20 X-ray crystal 
structures of CDK2 (no mutations, a resolution below 2.5 Å and the same aminoacid 
sequence). One of these crystal structures is that of the apo-enzyme (1hcl), whilst the other 
crystal structures contain either ATP (1hck and 1fin) or an inhibitor bound to the ATP site 
(1aqi, 1ckp, 1di8, 1dm2, 1eiv, 1eix, 1fvt, 1h0u, 1h0v, 1h0w, 1jsv, 1jvp, 1ke5, 1ke6, 1ke7, 
1ke8 and 1ke9). For the present study, and in accordance with the validation study of the 
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computer-aided de novo drug design algorithm that we employ,20 the crystal structure 1di8 
was used.  This structure was determined to a resolution of 2.2 Å.42 It presents an intermediate 
orientation of the hydrogen bonding groups in the hinge strand connecting the N- and C-
terminal domains in the ATP binding site.20 
Computer-aided de novo ligand design was carried out using the program Skelgen.19,20 This is 
a program that can incrementally construct and/or modify a ligand in the binding site of a 
target protein using a Monte Carlo simulated annealing optimisation algorithm. The program 
uses a set of common ring and acyclic fragments that are assembled together into a ligand 
structure following chemical rules. Ligand structures are modified through fragment 
additions, fragment removals and fragment mutations, as well as by molecular translations 
and rotations and conformational changes in torsional space. These modifications allow for 
previously incorporated fragments to be removed or replaced with different fragments, 
allowing the ligand to gradually satisfy the protein binding site constraints. This process is 
carried out in a stochastic manner to gradually optimise the interaction properties and 
chemical features of the generated ligand during the annealing optimisation. The assembled 
ligands must satisfy user-defined geometric constraints, such as those defining hydrogen bond 
distances and angles for pre-selected donor and acceptor groups and the steric constraints 
imposed by the structure of the binding site. Full details of this algorithm can be found 
elsewhere.19,20,44  The program was used to generate 200 molecular structures for each ligand 
design strategy (see below), producing a total of 600 scaffolds. 
The ligand structures generated with Skelgen were minimised using the Discover 3 module in 
InsightII 2000 (Accelrys) with the CFF forcefield.45 Additional torsional or out-of-plane 
restraints were used to ensure the planarity of aromatic or conjugated systems in some 
ligands. The protein was kept rigid in its original crystal structure conformation throughout 
the minimisations; however, hydrogen atoms in any aminoacid in the binding site with at least 
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one atom within 3.5 Å of the ligand were allowed to re-orient in order to optimise the 
hydrogen-bonding network between the ligand, the water molecule (if present) and the 
protein. The ligands were allowed full flexibility during the minimisations. Water molecules 
were kept in their original crystal structure positions but were allowed to re-orient their 
hydrogen atoms.  The energy minimisations were conducted in stages as described 
elsewhere18 to try to retain the original binding mode.  The minimisations were stopped when 
the energy gradient reached a value of less than 0.01 kcal/mol/Å. 
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Figure captions 
 
Figure 1. a) Superposition of the ligands found in the binding site of the crystal structures of 
CDK2. Cyan spheres represent crystallographically-observed water molecules. Green = 
chlorine, yellow = sulphur, red = oxygen, blue = nitrogen, grey = carbon, orange = 
phosphorous. b) The binding site of CDK2 (1di8) with its co-crystallised inhibitor. Yellow 
spheres indicate hydrogen bond acceptors and magenta spheres represent hydrogen bond 
donors. Cyan spheres represent tightly-bound water molecules. The size of the spheres is 
directly proportional to the degree of solvent accessibility of the hydrogen-bonding group. 
Figure 2. Chemical structure of the BMS-387032 inhibitor. 
Figure 3. a) Ligand generated in strategy B that combines the fragments shown in scaffolds 
6b and 7a in Table 2. b) Side view of the binding mode of the previous ligand, showing all 
typical sitepoints and water molecule HOH 100 in the same plane within the binding site. c) 
 21 
Ligand generated in strategy B that combines the interactions seen for scaffolds 11b and 15b; 
it also interacts with water molecule HOH 100. d) Ligand generated in strategy C that 
contains scaffold 16b superimposed into the binding site, shown clashing with water HOH 
100. 
 Figure 4. a) Chemical structure of the ligand shown in Figure 3a. Atoms marked with a star 
(*) represent atoms within hydrogen-bonding distance from the protein. b) Chemical structure 
of the ligand shown in Figure 3c. c) Chemical structure of the ligand seen in Figure 3d. 
 22 
Table 1. Summary of strategies for de novo ligand generation 
Strategy Sitepoints used 
A 
= Standard 
Glu 81 C=O 
Leu 83 NH 
Leu 83 C=O 
B  
= Including water 
Glu 81 C=O 
Leu 83 NH 
Leu 83 C=O 
HOH 100 
C 
= Additional sitepoints 
Glu 81 C=O 
Leu 83 NH 
Leu 83 C=O 
Asp 86 Oδ 
Asp 86 N 
Lys 89 Nζ 
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Table 2. Classification of molecular scaffolds according to the ligand design strategy 
A = Standard B = Including water C = Additional sitepoints 
1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 
5a, 5b, 6a, 6b, 7a, 7b, 8a, 8b, 
9a, 9b, 10a, 10b, 11a, 11b, 
12a, 13a, 13b, 14a, 14b, 15a, 
15b, 16a, 16b, 17a, 17b 
1a, 2b, 3b, 4a, 5a, 6b, 8a, 8b, 
9a, 9b, 10a, 10b, 11b, 13b, 
14b, 15b, 17a 
1a, 1b, 2b, 3a, 3b, 4a, 4b, 5a, 
5b, 6a, 6b, 7a, 7b, 8a, 8b, 9a, 
9b, 10a, 10b, 11a, 11b, 13b, 
14b, 15a, 15b, 16b, 17b  
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Figure 4 
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